Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic Predictors of Escitalopram Response in Depression and Panic Disorder
NCT03927950Phase 4Completed
- Sponsor
- University of Tartu
- Start
- Jan 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of escitalopram in major depressive disorder (MDD) and panic disorder, sponsored by University of Tartu. Primary endpoint: Montgomery-Asberg's Depression Rating Scale at 12 weeks. Started Jan 2007; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)panic disorder
Beyond the preview
Go deeper on NCT03927950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927950.